Rheumatoid Arthritis MedDRA version: 21.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Conditions
Sponsors
Dr. Reddy’s Laboratories S.A.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female subjects aged 18 years or older who have provided valid written informed consent. 2. Subjects with a diagnosis of active RA who are eligible for the subsequent treatment course with US rituximab or EU rituximab according to the clinical judgment of the investigator. 3. Documented evidence that subject has received at least 1 full course comprising two 1000 mg infusions of either US rituximab at least 16 weeks prior to the randomization visit or EU rituximab at least 24 weeks prior to the day of randomization visit. Note: Subjects are only eligible if they have received the prior US or EU-rituximab course within the 15 months prior to the date of randomization. 4. Subjects receiving a stable dose of weekly MTX for at least 4 weeks prior to randomization (between 7.5 mg and 25 mg) and folic acid (at least 5 mg per week). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 120 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20
Exclusion criteria
Exclusion criteria: 1. Subjects with RA in functional Class IV 2. Subjects with human immunodeficiency virus (positive HIV1Ab or HIV2Ab), hepatitis B virus and/or hepatitis C virus infection, including those with positive results in the viral disease screening 3. Subjects with active tuberculosis (TB). Subjects with evidence of latent TB or a history of TB must have completed treatment or have initiated treatment for at least 1 month before the first dose of study treatment (Day 1). TB testing is required only if it is required by local regulations or practice. 4. Active systemic infection. 5. Severely immunocompromised. 6. History of hypersensitivity to either US rituximab or EU rituximab or any of its excipients. 7. Any serious illness or uncontrolled medical condition, including, but not limited to, severe infections, significant hepatic or renal disease, uncontrolled hypertension despite treatment (defined as blood pressure [BP] =160/95 mmHg), congestive heart failure (New York Heart Association [NYHA] Class III or IV), or other severe uncontrolled cardiac disease or uncontrolled diabetes with immediate risk of acute complications. 8. Any condition that in the opinion of the investigator represents an obstacle for study conduct and/or represents a potential unacceptable risk for subjects. 9. Requires treatment with any biological medicinal product during the study other than the study treatment. 10. Previous treatment with B-cell modulating or cell depleting biologic therapy, except US rituximab or EU rituximab. 11. Prior participation in this clinical trial or prior participation in any clinical trial with any monoclonal antibody within 12 months of screening or prior participation in any clinical trial within 3 months of screening or within 5 half-lives of the investigational drug or until the expected PD effect has returned to baseline, whichever is longer. 12. Treatment with other biologic DMARDs, or Janus kinase (JAK) inhibitors administered within 12 weeks before the first dose of rituximab of the prior treatment course onwards till the date of randomization. 13. Subjects with the following laboratory abnormalities: • Subjects with screening total white blood cell count 2 × upper limit of normal (ULN). A single parameter >2 × ULN can be re-checked as soon as possible, at least prior to randomization, if required as per the investigator’s discretion. • Creatinine clearance (Cockcroft & Gault formula) of less than 50 mL/min. 14. History of vaccination with live vaccines within 4 weeks of the first dose of study treatment (Day 1) or known to require live vaccines during the study. 15. Lactating or pregnant female. 16. Women of childbearing potential who do not consent to use highly effective methods of birth control during treatment and for at least 12 months after the last administration of study treatment. Note: Per the Clinical Trial Facilitation Group (CTFG) guidelines 2014, a woman is considered of childbearing potential if fertile, following menarche until becoming postmenopausal (i.e., no menses for 12 months without an alternative medical cause) unless permanently sterile through hysterectomy, bilateral salpingectomy, and bilateral oophorectomy). Highly effective birth control measures per CTFG guidelines 2014 include the foll
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the immunogenicity of transitioning subjects with RA to DRL_RI (biosimilar rituximab) from US rituximab/EU rituximab to continued treatment with US rituximab/EU rituximab. To assess the safety of transitioning subjects with RA to DRL_RI from US rituximab/EU rituximab to continued treatment with US rituximab/EU rituximab.;Secondary Objective: None;Primary end point(s): The immunogenicity endpoint is: • The incidence of anti-drug antibodies (ADA), including titer and neutralizing antibodies (NAb). The primary safety endpoints are: • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). • Incidence of anaphylactic reactions, hypersensitivity reactions, and IRRs. Other safety endpoints are: • Clinical laboratory parameters • Vital signs • Twelve-lead electrocardiogram (ECG) • Physical examination;Timepoint(s) of evaluation of this end point: • Samples for detection of ADA will be collected at Weeks 4, 8, and 12 (EOS/ET visit). • Samples for detection of NAB will be collected at Weeks 4, 8, and 12 (EOS/ET visit). • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) - on occurrence. • Incidence of anaphylactic reactions, hypersensitivity reactions, and IRRs - on occurrence. • Clinical laboratory assessments, vital signs measurement and Physical examination will be performed at the screening, on Day 1, Day 15, and at Weeks 4, 8, and 12 (EOS/ET) visits. • Twelve-lead electrocardiogram (ECG) - at the screening and End of Treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): None;Timepoint(s) of evaluation of this end point: None | — |
Countries
Bulgaria, Czech Republic, Germany, Hungary, Lithuania, Poland, United States
Contacts
Public ContactNarendra Maharaj
Dr. Reddy’s Laboratories Ltd.
Outcome results
None listed